SCHEMBL19973941

SCHEMBL19973941

CCCCNC(=S)NC[C@H](c1cccs1)c1c[nH]c2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.74
MEN1 O00255 3/20 0.74
POLB P06746 1/20 0.53
RAD52 P43351 1/20 0.53
MGAM O43451 2/20 0.52
GAA P10253 2/20 0.52
SI P14410 2/20 0.52
MGAM2 Q2M2H8 2/20 0.52
MAPT P10636 4/20 0.47
GPR84 Q9NQS5 2/20 0.44
FFAR1 O14842 1/20 0.44
CYP2D6 P10635 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
KCNH2 Q12809 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MTNR1A P48039 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973942 1.00 KMT2A (0.74) KMT2AMEN1POLBRAD52MGAM
SCHEMBL21273590 0.97 KMT2A (0.70) KMT2AMEN1POLBRAD52MGAM
SCHEMBL19982166 0.96 KMT2A (0.68) KMT2AMEN1POLBRAD52MGAM
SCHEMBL21273523 0.96 KMT2A (0.68) KMT2AMEN1POLBRAD52MGAM
SCHEMBL19973397 0.94 KMT2A (0.64) KMT2AMEN1POLBRAD52MGAM
SCHEMBL19973396 0.94 KMT2A (0.64) KMT2AMEN1POLBRAD52MGAM
SCHEMBL19973398 0.90 KMT2A (0.58) KMT2AMEN1POLBRAD52MGAM
SCHEMBL19973399 0.90 KMT2A (0.58) KMT2AMEN1POLBRAD52MGAM
SCHEMBL28599107 0.88 KMT2A (0.89) KMT2AMEN1POLBRAD52GAA
SCHEMBL19973394 0.86 GAA (0.56) KMT2AMEN1POLBRAD52MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256502-A1 ORGANIC COMPOUNDS HOX THERAPEUTICS LIMITED (GB) 2019-08-22 US disclosed
WO-2018051114-A1 ORGANIC COMPOUNDS HOX THERAPEUTICS LIMITED (GB) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256502-A1 ORGANIC COMPOUNDS POU2F1, BRIX1, PAX3 KMT2A 702/4885MEN1 3544/4885POLB 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.